These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32865289)

  • 1. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis.
    Nielsen VW; Lund TT; Gniadecki R; Olsen RH; Nissen CV; Schwensen JFB; Thomsen SF
    Dermatol Ther; 2020 Nov; 33(6):e14258. PubMed ID: 32865289
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis.
    Di Cesare A; Tronconi G; Fastame TM; Rosi E; Pescitelli L; Ricceri F; Prignano F
    Dermatol Ther; 2020 May; 33(3):e13435. PubMed ID: 32306527
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease.
    Viscido A; Latella G
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154-155. PubMed ID: 33207902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of Dermatology.
    García-Hidalgo L; Méndez-Flores S; Carrillo-Vázquez S; Estrada-Aguilar L; García-Salazar MDR; Gómez-Flores M; López-Tello A; Charli-Joseph Y; Maldonado-García C; Serrano-Jaén L
    Gac Med Mex; 2020; 156(Supl):1-14. PubMed ID: 32484168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab.
    Aarebrot AK; Solberg SM; Davies R; Bader LI; Holmes TD; Gavasso S; Bryceson YT; Jonsson R; Sandvik LF; Appel S
    Br J Dermatol; 2018 Aug; 179(2):371-380. PubMed ID: 29274242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AVT02: An Adalimumab Biosimilar.
    Kang C
    Clin Drug Investig; 2022 Oct; 42(10):875-878. PubMed ID: 36181655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series.
    Khandpur S; Sondhi P; Taneja N; Sharma P; Das D; Sharma A; Sreenivas V
    J Am Acad Dermatol; 2020 Jul; 83(1):248-251. PubMed ID: 32087993
    [No Abstract]   [Full Text] [Related]  

  • 12. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.
    Dapavo P; Vujic I; Fierro MT; Quaglino P; Sanlorenzo M
    J Am Acad Dermatol; 2016 Oct; 75(4):736-739. PubMed ID: 27473452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.
    Lund T; Sand C; Gniadecki R; Thomsen SF
    Dermatol Ther; 2019 May; 32(3):e12846. PubMed ID: 30697879
    [No Abstract]   [Full Text] [Related]  

  • 14. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
    Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
    Kaniewska M; Rosołowski M; Rydzewska G
    Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis.
    Killion L; Alsharqi A; Kirby B
    Clin Exp Dermatol; 2023 Mar; 48(4):397-398. PubMed ID: 36745550
    [No Abstract]   [Full Text] [Related]  

  • 17. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
    Phan DB; Jourdain H; González-Quesada A; Zureik M; Rivera-Díaz R; Sahuquillo-Torralba A; Descalzo-Gallego MA; Lunt M; Garcia-Doval I; Sbidian E; Warren RB; Yiu ZZN
    BMJ Open; 2023 Jul; 13(7):e075197. PubMed ID: 37451726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.